Testing effectiveness (Phase 2)Ended earlyNCT05613868What this trial is testingTPN-101 in Aicardi-Goutières Syndrome (AGS)Who this might be right forAicardi-Goutières Syndrome (AGS) Transposon Therapeutics, Inc. 4
Testing effectiveness (Phase 2)Study completedNCT04731103What this trial is testingInhibition of Reverse Transcription in Aicardi-Goutières SyndromeWho this might be right forAicardi-Goutières Syndrome University of Edinburgh 13
Not applicableApproved For MarketingNCT01724580What this trial is testingCompassionate Use Protocol for the Treatment of Autoinflammatory SyndromesWho this might be right forChronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)Juvenile Dermatomyositis (JDM)Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)+1 more Eli Lilly and Company
Not applicableStudy completedNCT06898372What this trial is testingEvaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières SyndromeWho this might be right forAicardi-Goutières Syndrome (AGS) IRCCS Fondazione Stella Maris 24
Testing effectiveness (Phase 2)Study completedNCT03921554What this trial is testingJAK Inhibitor Treatment in AGSWho this might be right forAicardi Goutieres Syndrome Adeline Vanderver, MD 54
Testing effectiveness (Phase 2)WithdrawnNCT03304717What this trial is testingReverse Transcriptase Inhibitors in Aicardi Goutières SyndromeWho this might be right forAicardi Goutières Syndrome Children's Hospital of Philadelphia
Testing effectiveness (Phase 2)Study completedNCT02363452What this trial is testingReverse Transcriptase Inhibitors in AGSWho this might be right forAicardi-Goutières Syndrome (AGS) Assistance Publique - Hôpitaux de Paris 11